Den Boer AT - Search Results

1

The role of CD40 in peripheral T cell tolerance and immunity.

Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: den boer at. J Mol Med (Berl). 2000;78(7):363-71. doi: 10.1007/s001090000126. J Mol Med (Berl). 2000. PMID: 11043379 Review.

2

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ. van Mierlo GJ, et al. Among authors: den boer at. J Immunol. 2004 Dec 1;173(11):6753-9. doi: 10.4049/jimmunol.173.11.6753. J Immunol. 2004. PMID: 15557168 Free article.

3

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. van Mierlo GJ, et al. Among authors: den boer at. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. doi: 10.1073/pnas.082107699. Epub 2002 Apr 2. Proc Natl Acad Sci U S A. 2002. PMID: 11929985 Free PMC article.

4

The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. den Boer AT, et al. J Immunol. 2004 May 15;172(10):6074-9. doi: 10.4049/jimmunol.172.10.6074. J Immunol. 2004. PMID: 15128791 Free article.

5

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. den Boer AT, et al. Cancer Res. 2005 Aug 1;65(15):6984-9. doi: 10.1158/0008-5472.CAN-04-3344. Cancer Res. 2005. PMID: 16061684 Free article.

6

In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.

Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R. Diehl L, et al. Among authors: den boer at. J Immunol. 2002 Apr 15;168(8):3755-62. doi: 10.4049/jimmunol.168.8.3755. J Immunol. 2002. PMID: 11937526 Free article.

7

Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.

Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE. Schurmans LR, et al. Among authors: den boer at. J Immunol. 2001 Nov 15;167(10):5832-7. doi: 10.4049/jimmunol.167.10.5832. J Immunol. 2001. PMID: 11698457 Free article.

8

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE. den Boer AT, et al. J Immunol. 2001 Sep 1;167(5):2522-8. doi: 10.4049/jimmunol.167.5.2522. J Immunol. 2001. PMID: 11509591

9

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: den boer at. Nat Med. 1999 Jul;5(7):774-9. doi: 10.1038/10495. Nat Med. 1999. PMID: 10395322

10

Successful immunotherapy of an intraocular tumor in mice.

Schurmans LR, den Boer AT, Diehl L, van der Voort EI, Kast WM, Melief CJ, Toes RE, Jager MJ. Schurmans LR, et al. Among authors: den boer at. Cancer Res. 1999 Oct 15;59(20):5250-4. Cancer Res. 1999. PMID: 10537305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results